Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $3.99B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.91M
Average 2.67M
DFTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Definium Therapeutics, Inc.NASDAQ: DFTX
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income dips below year-ago levels
Q3 FY2026 net income of $50.96M (cash outflow) fell 24.2% year over year, behind the +100.8% change in trailing-twelve-month net income. Sequentially, it fell 67.9% from the prior quarter. Over 3 fiscal years it compounded at +47.9% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$199.16M (+8.4%) for the fiscal year ending Dec 2026, a slowdown from the +69.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$50.96M-67.9% QoQ
- Last fiscal yearDec 2025
- -$183.79M+69.1% YoY
- LTMSep 2026
- -$337.48M+100.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -24.2% | -3.5% | +20.8 pp |
| 1 year | +69.1% | +8.4% | -60.8 pp |
| 3-year CAGR | +47.9% | -32.4% | -80.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (183.79M) USD
- Year-over-year change
- -69.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (183.79M) | -69.1% |
| FY2024 | 2024-12-31 | (108.68M) | -13.5% |
| FY2023 | 2023-12-31 | (95.73M) | -68.6% |
| FY2022 | 2022-12-31 | (56.8M) | +39.0% |
| FY2021 | 2021-12-31 | (93.04M) | — |
Net Income vs competitors
How DFTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +100.8% is the 2nd highest of 9, against a peer median of +24.6%.
- Over three fiscal years its annual growth of +47.9% compares with a peer median of +25.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $108.22B USD | — | +109.1% | — | |
| LTM Sep 2026 | $359.43M USD | +31.6% | +12.3% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $337.48M USD | +100.8% | +47.9% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M USD | -13.8% | +21.9% | — |
| LTM Mar 2026 | $199.48M USD | +146.3% | +75.1% | — | |
| LTM Jun 2026 | $191.64M USD | -22.4% | -0.7% | 24.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.28M USD | +34.6% | +118.7% | 536.4% |
| LTM Mar 2026 | $74.31M USD | +17.6% | +31.7% | — | |
| LTM Mar 2026 | $56.41M USD | +34.0% | +29.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $39.17M USD | — | +20.7% | — |
| FY2025 | A$12.15M AUD | -36.5% | -1.8% | 223.4% | |
| Peer median (excluding DFTX) | — | +24.6% | +25.5% | 223.4% | |
Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.04M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Depreciation & Amortization | 2.62M | 3.18M | 3.16M | 527K | 0 |
| Deferred Income Tax | (1.16M) | 0 | (2.03M) | 0 | 0 |
| Stock-Based Compensation | 42.72M | 13.71M | 15.49M | 16.91M | 20.1M |
| Change in Working Capital | 1.88M | (3.78M) | 6.28M | (3.34M) | 9.44M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.28M | (2.06M) | 2.03M | (2.13M) | 3.34M |
| Other Working Capital | 598K | (1.73M) | 4.26M | (1.22M) | 6.1M |
| Other Non-Cash Items | 1.16M | (6.45M) | 8.46M | 15.45M | 22.7M |
| Operating Cash Flow | (45.82M) | (50.14M) | (64.37M) | (79.13M) | (131.56M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | (297K) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (268.36M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 116.75M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (297K) | 0 | 0 | 0 | (151.61M) |
| Debt Repayment | 0 | 0 | 14.16M | 10.86M | 20M |
| Common Stock Issued | 81.92M | 42.3M | 7.53M | 250M | 259.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.9M | 16.75M | 163K | (7.66M) | (12.63M) |
| Financing Cash Flow | 98.82M | 59.05M | 21.85M | 253.2M | 267.27M |
| Effect of Forex Changes | 742K | (309K) | 79K | (30K) | (7K) |
| Net Change in Cash | 53.45M | 8.6M | (42.44M) | 174.04M | (15.9M) |
| Free Cash Flow | (45.82M) | (50.14M) | (64.37M) | (79.13M) | (131.56M) |
Definium Therapeutics, Inc.
NASDAQ:DFTX
Intrinsic Alpha fair value
Locked
Current Price
$29.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.